REBOOT will test whether a combination of belimumab and rituximab is safer and more effective than rituximab alone for treating Primary Membranous Nephropathy.

BEAT-MS will compare autologous hematopoietic stem cell transplant (AHSCT) to the most effective standard treatment in MS.

VIBRANT will determine whether adding VIB4920 to standard therapy is more effective than standard therapy alone for treating lupus nephritis.